余爽  研究员  

研究方向:

电子邮件:yush@sibet.ac.cn

电       话:13951103916

通讯地址:

简       历:

余爽,博导,PI,从事干细胞与再生医学领域研究近二十年。2001年华中科技大学同济医学院七年制临床医学本科及硕士学位,2004年首都医科大学神经生物学博士学位,2004-2016加入德国慕尼黑马普研究所,历任博士后、高级研究人员、欧盟Switchbox项目负责人。2016年回国后被聘为中国科学院苏州生物科学技术研究所研究员。

回国后获批2017年江苏省双创团队,2018年江苏省“333” 中青年科学技术带头人,2019年姑苏重大创新创业人才等。目前主持项目包括国家干细胞重点研发专项、中国科学院战略先导专项A、国家自然科学基金、江苏省重点研发专项等多项国家和省市级重大课题。以第一作者和通讯作者的身份发表多篇SCI论文,单篇影响因子~10。参与出版英文专著1部。目前致力于下列研究:(1)干细胞/类器官培养及相关的细胞替代疗法在皮肤功能性重建中的应用;(2)干细胞/外泌体技术在神经精神疾病中的应用及其机制探索。

获奖及荣誉:

12017年江苏省创新创业人才

22018年江苏省“333高层次人才培养工程”第三层次

32019年姑苏创新创业人才

 

社会任职:

研究方向:

1)干细胞/类器官培养及相关的细胞替代疗法在重大疾病中的应用;

2)神经精神疾病的分子机制及其早期干预性研究;

3)与细胞替代疗法相关的医疗仪器研发及其在重大疾病的应用研究。

承担项目情况:

1、国家重点研发计划“干细胞研究与器官修复”:物理性因素调控组织干细胞促进创伤后组织原位再生修复的机制与新策略(课题负责人,总经费2600万元,主持经费650万元)

2、中科院战略性先导科技专项(A类)器官重建与制造:三维培养及人工皮肤三维重建装置为基础的皮肤类器官构建(主持,经费:300万元)

3、姑苏重大创新团队项目:干细胞关键技术研发及其核心装备产业化开发(联合主持,经费:1000万元)。

4、国家自然科学基金青年项目:脑源性神经营养因子干预早年糖皮质激素相关精神障碍的可行性研究(主持,经费20万元)

5、江苏省重点研发计划:基因工程结合智能生物材料重编程人星型胶质细胞治疗帕金森病的临床前研究(主持,经费:150万元)。

6、省“333”科研项目:多能干细胞及智能生物材料为基础的拟纹状体组织构建及对PD大鼠模型的疗效研究(主持)

代表论著:

1.         Zhang L, Yan X, An L, Wang M, Xu X, Ma Z, Nie M, Du F, Zhang J, Yu S*. Novel pneumatically assisted atomization device for living cell delivery and application of sprayed mesenchymal stem cells in skin regeneration. Bio design and manufacturing. 2022; 5, 220–232.

2.         Zhang YC, Wang JW, Wu Y, Tao Q, Wang FF, Wang N, Ji XR, Li YG, Yu S*, Zhang JZ. Multimodal Magnetic Resonance and Fluorescence Imaging of the Induced Pluripotent Stem Cell Transplantation in the Brain. Molecular Biology, 2022

3.         Wang NN, Ji XR, Wu Y, Zhou SC, Peng HY, Wang JW, Yu S*, Zhang JZ. The Different Molecular Code in Generation of Dopaminergic Neurons from Astrocytes and Mesenchymal Stem Cells. Int J Mol Sci. 2021; 22(22): 12141

4.         Zhou Y, Zhou JH, Xu X, Du FZ, Nie MT, Hu LZ, Ma YH, Liu MM, Yu S*, Zhang JZ, Chen YG. Matrigel/umbilical cord-derived mesenchymal stem cells promote granulosa cell proliferation and ovarian vascularization in a mouse model of premature ovarian failure. Stem Cells and Development. 2021; 30(15):782-796

5.         An L, Tao Q, Wu Y, Wang N, Liu Y, Wang F, Zhang L, Shi A, Zhou X, Yu S*, Zhang J. Synthesis of SPIO nanoparticles and the subsequent applications in stem cell labeling for Parkinson's disease. Nanoscale Res Lett, 2021, 16:107

6.         Liu Y, Zhou Y, Huang K-H, Fang X, Li Y, Wang F, An L, Chen Q, Zhang Y, Shi A, Yu S*, Jingzhong Zhang. Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor. CELL PROLIFERATION, 2020;00:e12858.

7.         Chen Q, Wang F, Zhang Y, Liu Y, An L, Ma Z, Zhang J, Yu S*. Neonatal DEX exposure leads to hyperanxious and depressive-like behaviors as well as a persistent reduction BDNF expression in developmental stages. Biochemical and Biophysical Research Communications, 2020, Vol.527(1): 311-316

8.         Liu Y, Song H, Yu S, Huang K-H, Ma X, Zhou Y, Yu S*, Zhang J, Chen L. Protein Kinase D3 promotes the cell proliferation by activating the ERK1/c-MYC axis in breast cancer. Journal of Cellular and Molecular Medicine. 2020 Feb;24(3):2135-2144

9.         Liu Y, Zhou Y, Huang KH, Li Y, Fang X, An L, Wang F, Chen Q, Zhang Y, Shi A, Yu S*, Zhang J. EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC. Aging. 2019 Dec 4;11(23):11054-11072.

10.     Moosecker S, Gomes PA, Yu S, Sotiropoulos I, Almeida OF. Activated PPARγ abrogates misprocessing of amyloid precursor protein, Tau missorting and synaptotoxicity. Front Cell Neuro, 2019 Jun 12;13:239

11.     Liu Y, Li J, Ma Z, Zhang J, Wang Y, Yu Z, Lin X, Xu Z, Su Q, An L, Zhou Y, Ma X, Yang Y, Wang F, Chen Q, Zhang Y, Wang J, Zheng H, Shi A, Yu S, Zhang J, Zhao W, Chen L. Oncogenic functions of Protein Kinase D2 and D3 in regulating multiple cancer-related pathways in breast cancer. Cancer Med. 2019;8(2):729-741.

12.     Yu S*Zutschi I, Stoffel R, Zhang JZ, Silva PV, Sousa N, et al. Antidepressant responsiveness in adulthood is permanently impaired after neonatal destruction of the neurogenic pool. Trans Psychiatry. 2017, Jan 3;7(1):e990.

13.     Yang S, Roselli F, Patchev AV, Yu S, Almeida OF. Non-receptor-tyrosine kinases integrate fast glucocorticoid signaling in hippocampal neurons. J Biol Chem. 2013 Aug 16;288(33):23725-39. 

14.     Zimmermann N, Zschocke J, Perisic T, Yu S, Holsboer F, Rein T. Antidepressants inhibit DNA methyltransferase 1 through reducing G9a levels. Biochem J. 2012 448:93-102.

15.     Yu S*, Yang S, Holsboer F, Sousa N, Almeida OF. Glucocorticoid regulation of astrocytic fate and function. PLoS One. 2011;6(7):e22419

16.     Yu S*, Patchev AV, Wu Y, Lu J, Holsboer F, Zhang JZ, Sousa N, Almeida OF. Depletion of the neural precursor cell pool by glucocorticoids. Ann Neurol. 2010; 67(1):21-30. 

17.     Yu S*, Sousa N, Almeida OFX (2010) Apoptosis. In: Encyclopedia of Psychopharmacology. Ian P. Stolerman (ed). Springer. 

18.     Yu S, Holsboer F, Almeida OFX. Neuronal actions of glucocorticoids: focus on depression. Journal of Steroids Biology and Molecular Biology. 2008;108 (3-5): 300-309.

19.     Yu S, Zhang JZ, Xu Q. Genes associated with neuronal differentiation of precursors from human brain. Neuroscience. 2006;141(2):817-25. 

20.    Yu S, Zhang JZ, Zhao CL, Zhang HY, Xu Q. Isolation and characterization of the CD133+ precursors from the ventricular zone of human fetal brain by magnetic affinity cell sorting. Biotechnology letters. 2004; 26(14):1131-6.

*为通讯作者。